DE69006684D1 - Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit. - Google Patents

Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit.

Info

Publication number
DE69006684D1
DE69006684D1 DE90311995T DE69006684T DE69006684D1 DE 69006684 D1 DE69006684 D1 DE 69006684D1 DE 90311995 T DE90311995 T DE 90311995T DE 69006684 T DE69006684 T DE 69006684T DE 69006684 D1 DE69006684 D1 DE 69006684D1
Authority
DE
Germany
Prior art keywords
symptoms
composition
abstinence
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE90311995T
Other languages
English (en)
Other versions
DE69006684T2 (de
Inventor
William J Goldman
Thomas N Gates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23709269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69006684(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Publication of DE69006684D1 publication Critical patent/DE69006684D1/de
Application granted granted Critical
Publication of DE69006684T2 publication Critical patent/DE69006684T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69006684T 1989-11-02 1990-11-01 Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit. Revoked DE69006684T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43083789A 1989-11-02 1989-11-02

Publications (2)

Publication Number Publication Date
DE69006684D1 true DE69006684D1 (de) 1994-03-24
DE69006684T2 DE69006684T2 (de) 1994-06-09

Family

ID=23709269

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69006684T Revoked DE69006684T2 (de) 1989-11-02 1990-11-01 Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit.

Country Status (14)

Country Link
EP (1) EP0426479B1 (de)
JP (1) JPH03206052A (de)
KR (1) KR910009254A (de)
AT (1) ATE101515T1 (de)
AU (1) AU646230B2 (de)
CA (1) CA2028746C (de)
DE (1) DE69006684T2 (de)
ES (1) ES2057439T3 (de)
GR (1) GR1002097B (de)
IE (1) IE64953B1 (de)
IN (1) IN171746B (de)
NZ (1) NZ235877A (de)
PT (1) PT95753A (de)
ZA (1) ZA908775B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2130152T3 (es) * 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
CA2144155A1 (en) * 1992-09-29 1994-04-14 Robert T. Sims Ibuprofen-h2 antagonist combinations
GB9221414D0 (en) * 1992-10-13 1992-11-25 Glaxo Group Ltd Pharmaceutical compositions
US5648355A (en) * 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
ZA975444B (en) * 1996-06-20 1998-12-21 Mcneil Ppc Inc Acetaminophen and meclizine hydrochloride analgesics
WO1998058637A1 (en) * 1996-06-20 1998-12-30 Mcneil-Ppc Acetaminophen and diphenhydramine analgesics
DE19801811B4 (de) * 1998-01-19 2004-12-23 Stada Arzneimittel Ag Pharmazeutische Zubereitung zur oralen Verabreichung
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US7799766B2 (en) 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US20050220909A1 (en) 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
GB9911017D0 (en) * 1999-05-13 1999-07-14 Zeneca Ltd Pharmaceutical compositions
IL145220A0 (en) * 1999-05-20 2002-06-30 Par Pharmaceutical Inc Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
EP1189662A1 (de) * 1999-06-09 2002-03-27 Eli Lilly And Company Kombination zur behandlung von antipsychotikumsgebrauch-assozierte gewichtszunahme, enthaltend ein atypisches antipsychotikum und ein h2-antagonist
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20040082605A1 (en) * 2001-03-08 2004-04-29 Arne Eek Use
EP2163241A1 (de) 2001-06-01 2010-03-17 Pozen, Inc. Pharmazeutische Zusammensetzungen für die koordinierte Abgabe von NSAID
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040185032A1 (en) * 2003-03-18 2004-09-23 David Burrell Compositions and methods for treating colic
US7923043B2 (en) 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
US7776873B2 (en) * 2005-12-01 2010-08-17 Yuhan Corporation Method for treating damage to gastric mucosa
US8771643B2 (en) * 2008-01-04 2014-07-08 Schabar Research Associates Llc Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
US9050275B2 (en) 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
US9176146B2 (en) 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
US11331307B2 (en) 2020-07-15 2022-05-17 Schabar Research Associates, Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1398A (en) * 1981-09-04 1987-12-18 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
US4522826A (en) * 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4757060A (en) * 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers

Also Published As

Publication number Publication date
GR900100786A (el) 1992-04-17
CA2028746C (en) 1995-12-26
IE903946A1 (en) 1991-05-08
GR1002097B (en) 1995-12-28
ATE101515T1 (de) 1994-03-15
PT95753A (pt) 1991-09-30
ZA908775B (en) 1992-07-29
ES2057439T3 (es) 1994-10-16
IN171746B (de) 1992-12-26
EP0426479A1 (de) 1991-05-08
CA2028746A1 (en) 1991-05-03
AU6568990A (en) 1991-05-09
JPH03206052A (ja) 1991-09-09
AU646230B2 (en) 1994-02-17
NZ235877A (en) 1992-09-25
IE64953B1 (en) 1995-09-20
DE69006684T2 (de) 1994-06-09
EP0426479B1 (de) 1994-02-16
KR910009254A (ko) 1991-06-28

Similar Documents

Publication Publication Date Title
DE69006684D1 (de) Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit.
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
EA199900137A1 (ru) Замещенные пиридины в качестве избирательных ингибиторов циклооксигеназы-2
DE69433889D1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
BR9612423A (pt) Composto, composição farmacêutica, e, processo para tratar um estado doentio.
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
DK0696283T3 (da) 2-, 3,- 4,- 5,- 6,- 7,- 8,- 9,- og/eller 10 substituerede dibenzoxazepinforbindelser, lægemidler og anvendelser
DE69707372T2 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
ATE415965T1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
DE69327314D1 (de) Zusammensetzungen enthaltend Lipoprotein-Associated-Coagulation-Inhibitor (LACI) zur Herstellung eines Medikaments zur Behandlung von akuten oder chronischen Enzündungen
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
ATE110568T1 (de) Pharmazeutisches präparat zur behandlung des katarakts.
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
KR910002455A (ko) 아크릴산 유도체를 함유하는 제약 조성물 및 의약으로서 이들의 사용
DE69923698D1 (de) Verwendung von 3-(1h-imidazol-4-ylmethyl)-indan-5-ol zur herstellung eines medikamentes zur intraspinalen, intrathekalen und epiduralen anwendung
HUP9903928A2 (hu) Fenoxi-etil-amin új származékai,eljárás előállításukra, alkalmazásuk gyógyszerhatóanyagokként és ilyen vegyületeket tartalmazó gyógyászati készítmények
ATE73326T1 (de) Verwendung von l-carnitin zur herstellung eines arzneimittels zur behandlung von toxischen effekten, induziert durch die inhalation von halotan und anderen halogen enthaltenden allgemeinen anaesthetika.
ATE32514T1 (de) 3-(4'-aminobutylamino)-propylamino-bleomycinderivate, verfahren zur ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES8301230A1 (es) Un procedimiento para la preparacion de 1-fenil-5-amidotetrazoles.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation